SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotechnology Value Fund, L.P.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jorgen Jensen who wrote (472)3/4/1999 4:47:00 PM
From: scaram(o)ucheRead Replies (1) of 4974
 
Thursday March 4, 4:20 pm Eastern Time

U.S. FDA panel rejects Magainan diabetes drug

SILVER SPRING, Md., March 4 (Reuters) - A Food and Drug Administration panel
Thursday rejected the first topical treatment for infected foot ulcers that afflict millions of
diabetics worldwide.

The drug Locilex, an antibiotic cream made by biotechnology firm Magainin Pharmaceuticals
(Nasdaq:MAGN - news), was rejected because panel members were not convinced it worked better than other drugs, surgery
or simply doing nothing. (snip)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News